* Puma Biotechnology – Median p95HER2 levels were higher in
samples from patients who achieved a pCR with neratinib
The post BRIEF-Puma’s investigational drug PB272 was presented at the 2016 San Antonio Breast Cancer Symposium appeared first on NASDAQ.